Cell Therapy: T Cell Isolation From Whole Blood

For cell therapy developers, the starting material decision shapes everything downstream. Leukopaks have long dominated T cell isolation workflows, but their collection burden, scheduling delays, and higher costs create real friction in manufacturing timelines. Whole blood offers a compelling alternative: same-day collection, lower cost, and reduced patient burden. The challenge has been processing it efficiently without sacrificing T cell purity or viability.

This brochure shows how the CTS DynaCellect Magnetic Separation System and CTS Detachable Dynabeads CD4 and CD8 make whole blood a viable, scalable starting material by eliminating preprocessing steps like fractionation and washing. The result is a flexible, cGMP-aligned workflow that carries isolated T cells through to activation with CTS Detachable Dynabeads CD3/CD28. If your team is evaluating how to streamline T cell isolation, download this resource for further insights.